Breaking
Friday, June 19, 2026

Biopharma

🇺🇸 FDA Page 3

FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page

Global biopharma insights for investors & BD. Track drug development, M&A, and market trends shaping the pharmaceutical landscape.

Showing 25–36 of 69 articles

High impact AnalysisJun 2, 2026

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

oncology · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Vyome Holdings Q1 2026: FDA Filings and Financial Strength Signal Strategic Momentum

FDA · 10 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing

oncology · 8 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Top 10 U.S. Biopharma Clusters 2026

10 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

OhioHealth and Fairfield Medical Center Terminate Merger Plans

8 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal

muscular dystrophy · 13 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives

FDA · 10 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

White House Taps Amazon, GoodRx to Expand TrumpRx Generic Drug Access

FDA · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Eli Lilly's Strategic Vaccine Acquisitions: A New Era in Infectious Disease

FDA · vaccine · 6 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Eli Lilly Acquires Engage Bio to Advance Non-Viral Genetic Medicines

FDA · genetic medicines · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

TrumpRx Expands Generic Drug Offerings: Implications for Pharma BD and Investors

FDA · 10 min

Dr. Sarah Mitchell
High impact NewsJun 2, 2026

Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus

FDA · 6 min

Dr. Sarah Mitchell